國立虎尾科技大學 |

Treatment of cystic fibrosis and other rare lung diseases

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Treatment of cystic fibrosis and other rare lung diseases/ edited by Arata Azuma, Michael S. Schechter.
other author:	Azuma, Arata.
Published:	Basel :Springer Basel : : 2017.,
Description:	viii, 263 p. :ill., digital ; : 24 cm.;
Contained By:	Springer eBooks
Subject:	Cystic fibrosis - Treatment. -
Online resource:	http://dx.doi.org/10.1007/978-3-0348-0977-1
ISBN:	9783034809771

Treatment of cystic fibrosis and other rare lung diseases
Treatment of cystic fibrosis and other rare lung diseases[electronic resource] /edited by Arata Azuma, Michael S. Schechter. - Basel :Springer Basel :2017. - viii, 263 p. :ill., digital ;24 cm. - Milestones in drug therapy,2296-6056. - Milestones in drug therapy..

Part I Etiopathology and Genetics of Rare Lung Diseases -- Part II Treatment of Cystic Fibrosis -- Part III Treatment of Other Rare Lung Diseases.

This volume describes the pathogenesis and pathophysiology of several pulmonary diseases as well as their treatment. It also discusses the underlying genetic and molecular biological basis, which opens the way for new treatments for these conditions. It focuses on the treatment of cystic fibrosis including CFTR (cystic fibrosis transmembrane-conductance regulator) modulator therapies, drug therapies that augment airway surface liquid as well as anti-inflammatory and anti-infective therapies. Further topics include long-term, low-dose macrolide therapy for diffuse panbronchiolitis; novel agents for previously untreatable idiopathic pulmonary fibrosis; possible new treatments for pulmonary alveolar proteinosis (PAP); and multiple novel therapeutic targets for treating lymphangiomyomatosis. Research into these conditions has led to major advances in our understanding of the underlying genetic and molecular basis of this disease, and to dramatic improvements in survival and quality of life for affected individuals.

ISBN: 9783034809771

Standard No.: 10.1007/978-3-0348-0977-1doiSubjects--Topical Terms:

1069997
Cystic fibrosis
--Treatment.

LC Class. No.: RC858.C95

Dewey Class. No.: 616.372

Treatment of cystic fibrosis and other rare lung diseases
LDR:02199nam a2200325 a 4500 001 958667
003 DE-He213
005 20170201181627.0
006 m d
007 cr nn 008maaau
008 201118s2017 sz s 0 eng d
020 $a 9783034809771 $q (electronic bk.)
020 $a 9783034809757 $q (paper)
024 7 $a 10.1007/978-3-0348-0977-1 $2 doi
035 $a 978-3-0348-0977-1
040 $a GP $c GP
041 0 $a eng
050 4 $a RC858.C95
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
082 0 4 $a 616.372 $2 23
090 $a RC858.C95 $b T784 2017
245 0 0 $a Treatment of cystic fibrosis and other rare lung diseases $h [electronic resource] / $c edited by Arata Azuma, Michael S. Schechter.
260 $a Basel : $c 2017. $b Springer Basel : $b Imprint: Springer,
300 $a viii, 263 p. : $b ill., digital ; $c 24 cm.
490 1 $a Milestones in drug therapy, $x 2296-6056
505 0 $a Part I Etiopathology and Genetics of Rare Lung Diseases -- Part II Treatment of Cystic Fibrosis -- Part III Treatment of Other Rare Lung Diseases.
520 $a This volume describes the pathogenesis and pathophysiology of several pulmonary diseases as well as their treatment. It also discusses the underlying genetic and molecular biological basis, which opens the way for new treatments for these conditions. It focuses on the treatment of cystic fibrosis including CFTR (cystic fibrosis transmembrane-conductance regulator) modulator therapies, drug therapies that augment airway surface liquid as well as anti-inflammatory and anti-infective therapies. Further topics include long-term, low-dose macrolide therapy for diffuse panbronchiolitis; novel agents for previously untreatable idiopathic pulmonary fibrosis; possible new treatments for pulmonary alveolar proteinosis (PAP); and multiple novel therapeutic targets for treating lymphangiomyomatosis. Research into these conditions has led to major advances in our understanding of the underlying genetic and molecular basis of this disease, and to dramatic improvements in survival and quality of life for affected individuals.
650 0 $a Cystic fibrosis $x Treatment. $3 1069997
650 0 $a Lungs $x Diseases $x Treatment. $3 970020
650 1 4 $a Biomedicine. $3 593880
650 2 4 $a Pharmacology/Toxicology. $3 593882
650 2 4 $a Pneumology/Respiratory System. $3 668561
650 2 4 $a Internal Medicine. $3 668583
650 2 4 $a Immunology. $3 592892
700 1 $a Azuma, Arata. $3 1250984
700 1 $a Schechter, Michael S. $3 1250985
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
830 0 $a Milestones in drug therapy. $3 887606
856 4 0 $u http://dx.doi.org/10.1007/978-3-0348-0977-1
950 $a Biomedical and Life Sciences (Springer-11642)